A recent publication in this journal highlighted the lack of coordinated policy responses across Europe towards provision of abortion care during the current COVID-19 pandemic.1 In April 2020, during the period of total confinement (‘lockdown’) decreed by the French government, exceptional legislation was introduced to facilitate the provision of medical abortion at home. Before COVID-19, medical abortion was authorised at home until 7 weeks of amenorrhea and approved providers were midwives and doctors (general practitioners and obstetricians/gynaecologists), working in private offices or in public abortion clinics. The new regulations that were introduced increased the gestational limit for medical abortion up to 9 weeks (63 days’ amenorrhea) and also authorised telemedicine for consultations.2 At the same time, a new system was introduced with community pharmacies whereby the abortion provider could send a prescription for the abortion medications (mifepristone and misoprostol) by email to a pharmacy chosen by the woman. The pharmacist could then dispense the drugs directly to the woman and the pharmacy was then reimbursed by Public Health Insurance. With the former (pre-COVID-19) model it was the provider who bought the drugs at the pharmacy and gave them directly to the woman during …

中文翻译：

---

法国药物流产远程医疗：一项艰巨的挑战

该杂志最近发表的一篇文章强调，在当前的 COVID-19 大流行期间，整个欧洲缺乏对提供堕胎护理的协调一致的政策回应。 1 2020 年 4 月，在法国政府颁布的全面禁闭（“封锁”）期间，制定了特殊立法，以促进在家中进行药物流产。在 COVID-19 之前，在闭经 7 周前允许在家进行药物流产，批准的提供者是在私人办公室或公共流产诊所工作的助产士和医生（全科医生和产科医生/妇科医生）。引入的新法规将药物流产的妊娠限制提高到 9 周（闭经 63 天），并授权远程医疗进行会诊。 2 同时，社区药房引入了一个新系统，堕胎提供者可以通过电子邮件将堕胎药物（米非司酮和米索前列醇）的处方发送给妇女选择的药房。然后药剂师可以直接将药物分发给妇女，然后药房由公共健康保险报销。对于前一种（COVID-19 之前）模型，是由提供者在药房购买药物并在……期间直接将药物给妇女。